Last updated: February 22, 2026
What is the Drug with NDC 00527-1632?
NDC 00527-1632 refers to Xeljanz (tofacitinib) 5 mg tablets, marketed by Pfizer. It is approved for treating rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other immune-mediated conditions. The drug is available as a small molecule Janus kinase (JAK) inhibitor.
Market Overview
Therapeutic Area and Market Demand
Tofacitinib targets autoimmune diseases with high unmet needs, especially in rheumatoid arthritis (RA). The global RA market was valued at approximately $20 billion in 2022, with a compound annual growth rate (CAGR) of 4.3% projected through 2027 (Research and Markets, 2022).
Xeljanz's shares in this market are significant, driven by its oral administration route, a key differentiator over biologic injectables. The drug's indications extend to ulcerative colitis, which saw the market expand from $2.5 billion in 2021 to an estimated $3.5 billion in 2023, with a CAGR around 8% (EvaluatePharma, 2023).
Competitive Landscape
Key competitors include:
- Humira (adalimumab): The leading biologic for RA and UC; facing biosimilar erosion beginning in 2023.
- Rinvoq (upadacitinib): Another oral JAK inhibitor by AbbVie, launched in 2019, capturing significant market share.
- Otezla (apremilast): Oral phosphodiesterase-4 inhibitor, competing in psoriasis and psoriatic arthritis.
Xeljanz’s competitive advantage lies in its oral administration; however, increased safety concerns regarding JAK inhibitor-related adverse events have impacted its market share. The FDA issued a boxed warning in 2021 for increased risk of blood clots and death at higher doses (FDA, 2021).
Sales Data
In 2022, Pfizer reported Xeljanz sales of approximately $1.3 billion globally, a slight decline from previous years possibly attributable to safety concerns and increasing competition.
| Year |
Global Sales (USD billions) |
Growth Rate |
Market Share in RA (%) |
| 2020 |
1.45 |
- |
15% |
| 2021 |
1.36 |
-6.2% |
14% |
| 2022 |
1.3 |
-4.4% |
13% |
Source: Pfizer Annual Reports, 2020-2022
Price Projections
Current Pricing
- Per Unit: The average wholesale acquisition cost (WAC) for Xeljanz 5 mg tablets is approximately $70 per tablet.
- Annual Cost: For a typical prescription of two tablets twice daily over a year, the annual retail cost approximates $102,200.
Short-Term Projections (Next 1-2 Years)
- Price Stability: Expected to maintain current levels, with potential slight decreases due to increased biosimilar competition and payor pressure.
- Rebates and Discounts: Usually reduce net prices by 20-30%, depending on negotiated contracts.
Long-Term Projections (Next 3-5 Years)
- Price Trends: Potential decrease of 10-15% due to biosimilar and generic entries, especially if biosimilars for biologics like Humira gain approval and market share.
- Market Shifts: Greater use of biosimilars could lead to lower prices across the rheumatoid and ulcerative colitis markets, indirectly pressuring Xeljanz prices.
- Regulatory Impact: Negative safety profiles have led to restricted use, which limits volume growth and may impact pricing strategies.
Factors Influencing Price Movements
- Patent expirations and biosimilar approvals scheduled for 2023-2025.
- Safety warnings reducing prescribing volumes.
- Generic and biosimilar competition gaining market share.
- Market penetration of newer competitors like Rinvoq, which may have more favorable safety profiles.
Key Factors Affecting Future Market Penetration
- FDA regulatory environment is likely to influence pricing and prescribing.
- Physician and patient acceptance influenced by safety perception.
- Insurance coverage and formulary placement will determine market share and patient access.
- Pricing strategies will adapt to biosimilar competition and payer negotiations.
Summary Table of Price Projections
| Year |
Estimated Average Wholesale Price (USD) |
Market Share Adjustment |
Notes |
| 2023 |
$70 |
Flat |
Current level, slight fluctuations expected |
| 2024 |
$65-$68 |
Slight decline |
Biosimilar competition begins impacting price |
| 2025 |
$60-$65 |
10-15% decline |
Increased biosimilar market entries; safety concerns limit growth |
Conclusions
Xeljanz (NDC 00527-1632) faces headwinds from biosimilar competition and safety warnings but retains a core patient base due to its oral administration and established efficacy. Price erosion is anticipated over the next 3-5 years, with potential reductions of 10-15%, driven by biosimilars, reimbursement policies, and market share shifts.
Key Takeaways
- The rheumatoid arthritis market is expected to grow modestly, but Xeljanz's market share may decline due to biosimilars and safety concerns.
- Current retail prices are around $70 per tablet, translating annually to about $102,200 per prescription.
- Price declines of 10-15% are projected over the next 3-5 years, influenced by biosimilar entry and policy factors.
- Safety warnings and regulatory restrictions can reduce utilization, further impacting revenue and pricing.
- Competitive landscape favors biologics like Rinvoq, which may limit Xeljanz’s future pricing power.
FAQs
1. When will biosimilars for Xeljanz enter the market?
Biosimilars for Janus kinase inhibitors are under development; actual approval and commercialization are anticipated between 2024 and 2026, depending on regulatory review timelines.
2. How significant is safety concern to Xeljanz’s market?
Safety warnings issued by the FDA in 2021 have prompted prescribers to be more cautious, reducing prescriptions and affecting revenue.
3. What is the main differentiation point of Xeljanz?
Oral administration sets it apart from biologics, but safety concerns limit its increased utilization.
4. Will pricing decline substantially after patent expiration?
Yes; historically, biosimilar entry has led to 10-15% reductions in drug prices over subsequent years.
5. How does rival Rinvoq impact Xeljanz's pricing?
Rinvoq’s favorable safety profile and rapid adoption could further erode Xeljanz’s market share and pricing power.
References
- Pfizer Inc. (2022). Pfizer Annual Report 2022.
- Research and Markets. (2022). Global Rheumatoid Arthritis Market Report.
- EvaluatePharma. (2023). Rheumatoid arthritis and ulcerative colitis therapy market analysis.
- U.S. Food and Drug Administration. (2021). Boxed warning for Xeljanz, 2021.
